Pseudomonas aeruginosa bacteremia in patients with liver cirrhosis: a comparison with bacteremia caused by Enterobacteriaceae

BMC Infect Dis. 2013 Jul 19:13:332. doi: 10.1186/1471-2334-13-332.

Abstract

Background: This study was performed to detect risk factors for Pseudomonas aeruginosa bacteremia in patients with liver cirrhosis.

Methods: A retrospective case-control study was designed to identify risk factors for P. aeruginosa bacteremia in cirrhotic patients. The cases were cirrhotic patients with P. aeruginosa bacteremia and the controls were cirrhotic patients with Enterobacteriaceae bacteremia.

Results: Sixty-one cases and the same number of controls were enrolled. In a multivariate analysis, younger age {adjusted odds ratio (aOR) per one year: 0.96, 95% confidence interval: 0.93 - 0.99}, nosocomial acquisition (aOR 3.87, 95% confidence interval: 1.50 - 9.94), preexisting biliary disease (aOR 4.79, 95% confidence interval: 1.92 - 10.47), and recent exposure to immunosuppressive agent (aOR 3.10, 95% confidence interval: 1.23 - 7.82) were associated with P. aeruginosa bacteremia. In the case group the frequency of appropriate initial antibiotic regimens was considerably lower than in the control group: 29.5% vs. 65.6% (P <0.01). However, thirty day mortality did not differ significantly between cases and controls (19.7% vs. 24.6%).

Conclusions: Nosocomial acquisition, preexisting biliary disease, and recent use of immunosuppressive agents are strong predictive factors for P. aeruginosa bacteremia in cirrhotic patients.

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia / complications
  • Bacteremia / drug therapy
  • Bacteremia / microbiology*
  • Case-Control Studies
  • Enterobacteriaceae / isolation & purification
  • Enterobacteriaceae Infections / complications
  • Enterobacteriaceae Infections / drug therapy
  • Enterobacteriaceae Infections / microbiology*
  • Female
  • Humans
  • Liver Cirrhosis / drug therapy
  • Liver Cirrhosis / microbiology*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Odds Ratio
  • Pseudomonas Infections / complications
  • Pseudomonas Infections / drug therapy
  • Pseudomonas Infections / microbiology*
  • Pseudomonas aeruginosa
  • Risk Factors
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents